Gene · 8205
Papers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 2,064
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour. | World J Surg Oncol | 2022 | 36203174 | PubTator, text mining | PubMed |
| KLHDC8A Expression in Association with Macrophage Infiltration and Oxidative Stress Predicts Unfavorable Prognosis for Glioma. | Oxid Med Cell Longev | 2022 | 36199422 | PubTator, text mining | PubMed |
| Early death in a mouse model of Alzheimer's disease exacerbated by microglial loss of TAM receptor signaling. | Proc Natl Acad Sci U S A | 2022 | 36191221 | PubTator, text mining | PubMed |
| A novel necroptosis-related gene signature associated with immune landscape for predicting the prognosis of papillary thyroid cancer. | Front Genet | 2022 | 36186479 | PubTator, text mining | PubMed |
| PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC. | Comput Math Methods Med | 2022 | 36176741 | PubTator, text mining | PubMed |
| YAP/Smad3 promotes pathological extracellular matrix microenviroment-induced bladder smooth muscle proliferation in bladder fibrosis progression. | MedComm (2020) | 2022 | 36176734 | PubTator, text mining | PubMed |
| CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study. | Hereditas | 2022 | 36167571 | PubTator, text mining | PubMed |
| Macrophages in melanoma: A double‑edged sword and targeted therapy strategies (Review). | Exp Ther Med | 2022 | 36160877 | PubTator, text mining | PubMed |
| Host immune response against DENV and ZIKV infections. | Front Cell Infect Microbiol | 2022 | 36159640 | PubTator, text mining | PubMed |
| The Roles of Skin Langerhans Cells in Immune Tolerance and Cancer Immunity. | Vaccines (Basel) | 2022 | 36146458 | PubTator, text mining | PubMed |
| SPP1 Derived from Macrophages Is Associated with a Worse Clinical Course and Chemo-Resistance in Lung Adenocarcinoma. | Cancers (Basel) | 2022 | 36139536 | PubTator, text mining | PubMed |
| Characterizations of a novel peptide encoded by a circular RNA using in-silico analyses. | Biochem Biophys Res Commun | 2022 | 36137323 | PubTator, text mining | PubMed |
| Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. | Front Oncol | 2022 | 36132136 | PubTator, text mining | PubMed |
| Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. | Int J Urol | 2022 | 36122306 | PubTator, text mining | PubMed |
| RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma. | Front Pharmacol | 2022 | 36120364 | PubTator, text mining | PubMed |
| INHBB is a novel prognostic biomarker and correlated with immune infiltrates in gastric cancer. | Front Genet | 2022 | 36118865 | PubTator, text mining | PubMed |
| The Roles of Tumor-Associated Macrophages in Prostate Cancer. | J Oncol | 2022 | 36117852 | PubTator, text mining | PubMed |
Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. | Redox Biol | 2022 | 36108528 | PubTator, text mining | PubMed |
| Alcohol and HIV-Derived Hepatocyte Apoptotic Bodies Induce Hepatic Stellate Cell Activation. | Biology (Basel) | 2022 | 36101437 | PubTator, text mining | PubMed |
| MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. | Aging (Albany NY) | 2022 | 36098680 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8205/papers?page=29